Artemis Therapeutics

5 articles about Artemis Therapeutics

• Artemis Therapeutics Announces Two Recent Publications Highlighting Artemisone's Activity Against Human Cytomegalovirus And Malaria

  6/19/2018

  Preclinical Data Further Supports Potential For Treatment of HCMV and Malaria

• Data Presented At The 31st International Conference For Antiviral Research Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication

  6/12/2018

  Artemis Therapeutics, Inc. announced that new data on its lead product candidate, Artemisone

• New Data Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication

  6/7/2018

  Artemis Therapeutics, Inc. (OTCQB: ATMS), ("Artemis" or the "Company"), today announced that new data on its lead product candidate Artemisone shows it is a potent inhibitor of human cytomegalovirus (HCMV).

• Artemis Therapeutics Announces Issuance of European Patent for Artemisone for the Treatment of Viral Infections

  11/28/2017

  The European patent will provide intellectual property protection for the Artemisone program in key markets and is expected to expire no earlier than 2033.

• Artemis Therapeutics Receives Orphan Drug Designation From FDA for Artemisone for the Treatment of Malaria

  11/6/2017

  Artemis is now qualified to receive significant benefits throughout its orphan drug development program including more frequent FDA interactions, protocol assistance, and tax credits for clinical research costs.